This is an aggregated industry headline. Read the full story at FiercePharma →
Sanofi unit in Ireland chided by FDA over manufacturing flubs linked to Altuviiio
After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing further reprimand from the U.S. regulator.
By FiercePharma
· Jul 6, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx…
The WeekBriefing
The FDA has granted premarket approval to United Therapeutics' LungFX device, designed to assess donor lungs f…
The WeekPharmaceutical Technology ↗
Roche's breast cancer agreement with Astex is one of several oncology deals the Swiss pharma giant has inked i…